Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olesoxime oral suspension versus oral solution single-dose pharmacokinetics study in healthy volunteers
NL-OMON45676Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olesoxime in spinal muscular atrophy (SMA) (2 arms), sponsored by Roche. Primary endpoint: Pharmacokinetic properties of olesoxime oral suspension and oral solution. Started Oct 2016; status: active, not recruiting.
02
Drugs
olesoxime
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON45676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45676.